These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

474 related items for PubMed ID: 28599901

  • 1. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD.
    Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, de Zeeuw D, Eckardt KU, McMurray JJV, Claggett B, Lewis EF, Pfeffer MA.
    Am J Kidney Dis; 2017 Oct; 70(4):522-531. PubMed ID: 28599901
    [Abstract] [Full Text] [Related]

  • 2. Risks of Adverse Events in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
    Grams ME, Yang W, Rebholz CM, Wang X, Porter AC, Inker LA, Horwitz E, Sondheimer JH, Hamm LL, He J, Weir MR, Jaar BG, Shafi T, Appel LJ, Hsu CY, CRIC Study Investigators.
    Am J Kidney Dis; 2017 Sep; 70(3):337-346. PubMed ID: 28366517
    [Abstract] [Full Text] [Related]

  • 3. Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial.
    Jhund PS, McMurray JJ, Chaturvedi N, Brunel P, Desai AS, Finn PV, Haffner SM, Solomon SD, Weinrauch LA, Claggett BL, Pfeffer MA.
    Eur Heart J; 2015 Sep 21; 36(36):2463-9. PubMed ID: 26188211
    [Abstract] [Full Text] [Related]

  • 4. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
    Schutte E, Lambers Heerspink HJ, Lutgers HL, Bakker SJ, Vart P, Wolffenbuttel BH, Umanath K, Lewis JB, de Zeeuw D, Gansevoort RT.
    Am J Kidney Dis; 2015 Sep 21; 66(3):450-8. PubMed ID: 25987260
    [Abstract] [Full Text] [Related]

  • 5. Incident Atrial Fibrillation and the Risk of Congestive Heart Failure, Myocardial Infarction, End-Stage Kidney Disease, and Mortality Among Patients With a Decreased Estimated GFR.
    Massicotte-Azarniouch D, Kuwornu JP, Carrero JJ, Lam NN, Molnar AO, Zimmerman D, McCallum MK, Garg AX, Sood MM.
    Am J Kidney Dis; 2018 Feb 21; 71(2):191-199. PubMed ID: 29153994
    [Abstract] [Full Text] [Related]

  • 6. Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus.
    Lewis EF, Claggett B, Parfrey PS, Burdmann EA, McMurray JJ, Solomon SD, Levey AS, Ivanovich P, Eckardt KU, Kewalramani R, Toto R, Pfeffer MA.
    Am Heart J; 2015 Aug 21; 170(2):322-9. PubMed ID: 26299230
    [Abstract] [Full Text] [Related]

  • 7. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.
    Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, Eckardt KU, McMurray JJV, Weinrauch LA, Liu J, Claggett B, Lewis EF, Pfeffer MA.
    Diabetes Obes Metab; 2019 May 21; 21(5):1199-1208. PubMed ID: 30672083
    [Abstract] [Full Text] [Related]

  • 8. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD.
    Desai AS, Toto R, Jarolim P, Uno H, Eckardt KU, Kewalramani R, Levey AS, Lewis EF, McMurray JJ, Parving HH, Solomon SD, Pfeffer MA.
    Am J Kidney Dis; 2011 Nov 21; 58(5):717-28. PubMed ID: 21820220
    [Abstract] [Full Text] [Related]

  • 9. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
    Mc Causland FR, Claggett B, Burdmann EA, Chertow GM, Cooper ME, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA.
    Am J Kidney Dis; 2019 Mar 21; 73(3):309-315. PubMed ID: 30578152
    [Abstract] [Full Text] [Related]

  • 10. Risk of end-stage renal disease and death after cardiovascular events in chronic kidney disease.
    Sud M, Tangri N, Pintilie M, Levey AS, Naimark D.
    Circulation; 2014 Aug 05; 130(6):458-65. PubMed ID: 24899688
    [Abstract] [Full Text] [Related]

  • 11. Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT).
    Theilade S, Claggett B, Hansen TW, Skali H, Lewis EF, Solomon SD, Parving HH, Pfeffer M, McMurray JJ, Rossing P, TREAT investigators.
    J Hum Hypertens; 2016 Jan 05; 30(1):46-52. PubMed ID: 25810068
    [Abstract] [Full Text] [Related]

  • 12. Race/Ethnicity and Cardiovascular Outcomes in Adults With CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic CRIC Studies.
    Lash JP, Ricardo AC, Roy J, Deo R, Fischer M, Flack J, He J, Keane M, Lora C, Ojo A, Rahman M, Steigerwalt S, Tao K, Wolf M, Wright JT, Go AS, CRIC Study Investigators.
    Am J Kidney Dis; 2016 Oct 05; 68(4):545-553. PubMed ID: 27209443
    [Abstract] [Full Text] [Related]

  • 13. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial.
    Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A, Pérez de Jose A, Cedeño S, Linares T, Luño J.
    Am J Kidney Dis; 2015 Apr 05; 65(4):543-9. PubMed ID: 25595565
    [Abstract] [Full Text] [Related]

  • 14. Echocardiographic Measures and Estimated GFR Decline Among African Americans: The Jackson Heart Study.
    Zelnick LR, Katz R, Young BA, Correa A, Kestenbaum BR, de Boer IH, Bansal N.
    Am J Kidney Dis; 2017 Aug 05; 70(2):199-206. PubMed ID: 28143672
    [Abstract] [Full Text] [Related]

  • 15. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.
    Carrero JJ, Evans M, Szummer K, Spaak J, Lindhagen L, Edfors R, Stenvinkel P, Jacobson SH, Jernberg T.
    JAMA; 2014 Mar 05; 311(9):919-28. PubMed ID: 24595776
    [Abstract] [Full Text] [Related]

  • 16. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
    Packham DK, Alves TP, Dwyer JP, Atkins R, de Zeeuw D, Cooper M, Shahinfar S, Lewis JB, Lambers Heerspink HJ.
    Am J Kidney Dis; 2012 Jan 05; 59(1):75-83. PubMed ID: 22051245
    [Abstract] [Full Text] [Related]

  • 17. Abrupt Decline in Kidney Function Before Initiating Hemodialysis and All-Cause Mortality: The Chronic Renal Insufficiency Cohort (CRIC) Study.
    Hsu RK, Chai B, Roy JA, Anderson AH, Bansal N, Feldman HI, Go AS, He J, Horwitz EJ, Kusek JW, Lash JP, Ojo A, Sondheimer JH, Townsend RR, Zhan M, Hsu CY, CRIC Study Investigators.
    Am J Kidney Dis; 2016 Aug 05; 68(2):193-202. PubMed ID: 26830447
    [Abstract] [Full Text] [Related]

  • 18. Prevalence and incidence of cardiovascular and renal diseases in type 1 compared with type 2 diabetes: A nationwide French observational study of hospitalized patients.
    Ducluzeau PH, Fauchier G, Herbert J, Semaan C, Halimi JM, Angoulvant D, Fauchier L.
    Diabetes Metab; 2023 May 05; 49(3):101429. PubMed ID: 36736892
    [Abstract] [Full Text] [Related]

  • 19. Kidney, Cardiac, and Safety Outcomes Associated With α-Blockers in Patients With CKD: A Population-Based Cohort Study.
    Hundemer GL, Knoll GA, Petrcich W, Hiremath S, Ruzicka M, Burns KD, Edwards C, Bugeja A, Rhodes E, Sood MM.
    Am J Kidney Dis; 2021 Feb 05; 77(2):178-189.e1. PubMed ID: 32920153
    [Abstract] [Full Text] [Related]

  • 20. Diabetes and end-stage renal disease synergistically contribute to increased incidence of cardiovascular events: a nationwide follow-up study during 1998-2009.
    Chang YT, Wu JL, Hsu CC, Wang JD, Sung JM.
    Diabetes Care; 2014 Feb 05; 37(1):277-85. PubMed ID: 23920086
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.